Injection of the immuno-modulatory drug α-galactosylceramide results in the recruitment of a large population of antigen-presenting cells into the liver of C57BL/6 mice

被引:4
作者
Delarbre, C [1 ]
Gachelin, G [1 ]
机构
[1] Inst Pasteur, INSERM, U 277, Unite Biol Mol Gene,Dept Immunol, F-75015 Paris, France
关键词
alpha-galactosylceramide; hepatic cells; large monocyte-like cells;
D O I
10.1016/j.micinf.2003.11.016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Injection of the immuno-modulatory drug a-galactosylceramide into C57BL/6 mice leads to the already known apoptosis of natural killer T (NKT) cells and to thus far undescribed large changes in the leukocyte populations of the liver. These changes are characterized by the recruitment of neutrophils and that of a population of large monocytic cells. The latter cells display the morphological and immunological features of natural suppressor cells. Their recruitment in the liver depends on the presence of NKT cells, most probably through the local release of cytokines and chemokines by activated NKT cells. We discuss the ubiquitous, long-term effects of a-galactosylceramide injection on immuno-pathological processes mediated through the NKT-triggered recruitment of a subset of large macrophages/monocytes. (C) 2003 Elsevier SAS. All rights reserved.
引用
收藏
页码:360 / 368
页数:9
相关论文
共 34 条
[1]   A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1+ macrophages that suppress naive CD4+ T cell proliferation via an IFN-γ and nitric oxide-dependent mechanism [J].
Atochina, O ;
Daly-Engel, T ;
Piskorska, D ;
McGuire, E ;
Harn, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (08) :4293-4302
[2]  
Azuma M, 2000, EUR J IMMUNOL, V30, P2138
[3]   Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells [J].
Bronte, V ;
Apolloni, E ;
Cabrelle, A ;
Ronca, R ;
Serafini, P ;
Zamboni, P ;
Restifo, NP ;
Zanovello, P .
BLOOD, 2000, 96 (12) :3838-3846
[4]  
Bronte V, 1999, J IMMUNOL, V162, P5728
[5]  
Bronte V, 1998, J IMMUNOL, V161, P5313
[6]  
Burdin N, 1998, J IMMUNOL, V161, P3271
[7]   Requirement for V(alpha)14 NKT cells in IL-12-mediated rejection of tumors [J].
Cui, JQ ;
Shin, T ;
Kawano, T ;
Sato, H ;
Kondo, E ;
Toura, I ;
Kaneko, Y ;
Koseki, H ;
Kanno, M ;
Taniguchi, M .
SCIENCE, 1997, 278 (5343) :1623-1626
[8]   Treatment with α-galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive [J].
Duthie, MS ;
Kahn, SJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (11) :5778-5785
[9]   Immunosuppression during acute Trypanosoma cruzi infection:: involvement of Ly6G (Gr1+)CD11b+ immature myeloid suppressor cells [J].
Goñi, O ;
Alcaide, P ;
Fresno, M .
INTERNATIONAL IMMUNOLOGY, 2002, 14 (10) :1125-1134
[10]   α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria [J].
Gonzalez-Aseguinolaza, G ;
de Oliveira, C ;
Tomaska, M ;
Hong, S ;
Bruna-Romero, O ;
Nakayama, T ;
Taniguchi, M ;
Bendelac, A ;
Van Kaer, L ;
Koezuka, Y ;
Tsuji, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) :8461-8466